Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Medpace (MEDP) stocks in Canada

Learn how to easily invest in Medpace stocks.

Medpace Holdings Inc
- $1.55 ( - 1.11%)

Medpace is a diagnostics & research business based in the US. Medpace stocks (MEDP.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $180.18 – an increase of 4.4% over the previous week. Medpace employs 4,700 staff and has a trailing 12-month revenue of around $1.2 billion.

How to buy stocks in Medpace

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MEDP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Medpace stock price (NASDAQ:MEDP)

Use our graph to track the performance of MEDP stocks over time.

Medpace shares at a glance

Information last updated 2022-05-12.
Latest market close$140.00
52-week range$126.95 - $231.00
50-day moving average $151.64
200-day moving average $181.04
Wall St. target price$140.00
PE ratio 24.4521
Dividend yield $0 (0%)
Earnings per share (TTM) $5.35

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Medpace stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Medpace price performance over time

Historical closes compared with the close of $140 from 2022-05-16

1 week (2022-05-11) 7.06%
1 month (2022-04-14) N/A
3 months (2022-02-18) -2.10%
6 months (2021-11-18) -38.13%
1 year (2021-05-18) -13.38%
2 years (2020-05-15) 65.96%
3 years (2019-05-17) 154.59%
5 years (2017-05-17) 435.78%

Is Medpace under- or over-valued?

Valuing Medpace stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medpace's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Medpace's P/E ratio

Medpace's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Medpace shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Medpace's PEG ratio

Medpace's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.97. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medpace's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Medpace's EBITDA

Medpace's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $236.4 million.

The EBITDA is a measure of a Medpace's overall financial performance and is widely used to measure a its profitability.

Medpace financials

Revenue TTM $1.2 billion
Operating margin TTM 17.74%
Gross profit TTM $701.3 million
Return on assets TTM 9.62%
Return on equity TTM 27.3%
Profit margin 16.47%
Book value $18.02
Market capitalisation $4.4 billion

TTM: trailing 12 months

Medpace share dividends

We're not expecting Medpace to pay a dividend over the next 12 months.

Medpace share price volatility

Over the last 12 months, Medpace's shares have ranged in value from as little as $126.945 up to $231. A popular way to gauge a stock's volatility is its "beta".

MEDP.US volatility(beta: 1.48)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medpace's is 1.4794. This would suggest that Medpace's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Medpace overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site